bg content top home

Smarter science.
Better health.

Target-icon

Our primary focus is on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.

VISIT OUR TARGET PAGE

Strategey-icon

Safer investment and faster to market by leveraging New Therapeutic Entities (NTEs) based on approved molecules with established safety and toxicity profiles.

VISIT OUR STRATEGY PAGE

Pipeline-icon

Molecules in development are expected to reach the market in 2 to 6 years, and occupy a lucrative niche between generics and New Chemical Entities (NCEs).

VISIT OUR PIPELINE PAGE

video

Capository™ is our proprietary and licensable delivery system for precise delivery of molecules that target conditions/diseases of the anorectal region.

WATCH OUR VIDEO

 

DECEMBER 2014 - TEL AVIV, ISRAEL

RDD Pharma has announced that patient enrollment and randomization has begun in a Phase 2a Double Blind Study to Examine the Effect of RDD 0315 on Anal Pressure and Fecal Incontinence in Spinal Cord Injury Patients.

RDD Pharma has announced that it has enrolled 34 Patients in a second Phase 2 Open Label Single-Dose Study to
Examine the Effect of RDD 1219 on Anal Fissure Pain and Healing.
A Phase 3 randomized, double-blind, placebo controlled study is planned for 1Q 2015.

 

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2014, RDD Pharma, Ltd. All rights reserved.

 

Menu
Go to top